Evotec announced the launch of a second research collaboration Indivumed GmbH focused on the discovery of innovative new therapies for non-small cell lung cancer ("NSCLC"). This comes on the back of an initial collaboration in colorectal cancer ("CRC") which successfully identified three novel targets within three months by leveraging Indivumed's multi-omics cancer database, IndivuType, in combination with Evotec's PanHunter bioinformatics platform. The new agreement in lung cancer highlights Ev ....
24 Jan 2020
Building on progress in precision medicine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Building on progress in precision medicine
Evotec SE (EVT:WBO) | 0 0 0.7% | Mkt Cap: 2,149m
- Published:
24 Jan 2020 -
Author:
Chris Redhead -
Pages:
5
Evotec announced the launch of a second research collaboration Indivumed GmbH focused on the discovery of innovative new therapies for non-small cell lung cancer ("NSCLC"). This comes on the back of an initial collaboration in colorectal cancer ("CRC") which successfully identified three novel targets within three months by leveraging Indivumed's multi-omics cancer database, IndivuType, in combination with Evotec's PanHunter bioinformatics platform. The new agreement in lung cancer highlights Ev ....